Search hospitals > Pennsylvania > Danville
Geisinger Medical Center
Claim this profileDanville, Pennsylvania 17822
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Leukemia
Conducts research for Lymphoma
Conducts research for Lung Cancer
785 reported clinical trials
43 medical researchers
Summary
Geisinger Medical Center is a medical facility located in Danville, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Leukemia, Lymphoma, Lung Cancer and other specialties. Geisinger Medical Center is involved with conducting 785 clinical trials across 859 conditions. There are 43 research doctors associated with this hospital, such as Jagadeesh Ramdas, Raghava Reddy Levaka Veera, Joseph J. Vadakara, and Sorab Gupta.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
Stage IV
Top PIs
Jagadeesh RamdasGeisinger Medical Center6 years of reported clinical research
Expert in Tumors
Expert in Cancer
45 reported clinical trials
94 drugs studied
Raghava Reddy Levaka VeeraGeisinger Wyoming Valley/Henry Cancer Center4 years of reported clinical research
Expert in Cancer
Studies Adenocarcinoma
19 reported clinical trials
43 drugs studied
Joseph J. VadakaraGeisinger Medical Center5 years of reported clinical research
Studies Leukemia
Studies Lymphoma
19 reported clinical trials
60 drugs studied
Sorab GuptaGeisinger Medical Center3 years of reported clinical research
Studies Cancer
Studies Squamous Cell Carcinoma
13 reported clinical trials
24 drugs studied
Clinical Trials running at Geisinger Medical Center
Breast Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Lymphoma
Acute Lymphoblastic Leukemia
Brain Tumor
Leukemia
Tumors
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Geisinger Medical Center?
Geisinger Medical Center is a medical facility located in Danville, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Leukemia, Lymphoma, Lung Cancer and other specialties. Geisinger Medical Center is involved with conducting 785 clinical trials across 859 conditions. There are 43 research doctors associated with this hospital, such as Jagadeesh Ramdas, Raghava Reddy Levaka Veera, Joseph J. Vadakara, and Sorab Gupta.
Where is Geisinger Medical Center located?
To reach Geisinger Medical Center in Danville, PA:
- Take I-80 and exit at Danville.
- Head south on US-11 for approximately 3 miles, then turn left onto N Academy Ave. The hospital will be on your right.
Who should I call to ask about financial aid or insurance network?
**Geisinger Medical Center Financial and Insurance Assistance:**
- **Financial Assistance:** Visit the Geisinger Medical Center website or call 800-640-4206.
- **Insurance Inquiries:**
- Geisinger Health Plan: 800-447-4000 (HMO, PPO with referral)
- PPO (no referral), Employer-based Self-funded Members, Geisinger Funding Alternative Plans: 800-504-0443
- GHP Family Medicaid: 855-227-1302
What insurance does Geisinger Medical Center accept?
Geisinger Medical Center accepts a variety of insurance plans, such as Geisinger Health Plan, Aetna, Capital Blue Cross, CIGNA of Pennsylvania, Highmark Blue Shield, and UnitedHealthcare. These plans include standard HMO, PPO, and TPA options. It's important to verify with your insurance provider about coverage for specific services or procedures at Geisinger Medical Center.
What awards or recognition has Geisinger Medical Center received?
Geisinger Medical Center, located in Danville, Pennsylvania, has been honored with the Magnet Recognition Program's highest national honor for professional nursing practice four times, a testament to its commitment to nursing excellence. This recognition extends to Geisinger Shamokin Area Community Hospital as well. Furthermore, two of its intensive care units have earned the national Beacon Award for Excellence, highlighting the hospital's dedication to outstanding patient and family care.